← All trials

NCT06444165

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jun 4, 2024
Primary completion
Jun 10, 2024
Completion date
Jun 10, 2024
First posted
Jun 5, 2024
Last posted
Jul 10, 2024
Enrollment
55
Arms / groups
1 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.